Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 3, 2015, Pages 1797-1801

  Shields, Ryan K ^a,b   Nguyen, M Hong ^a,b   Potoski, Brian A ^c,d   Press, Ellen G ^a   Chen, Liang ^c   Kreiswirth, Barry N ^c   Clarke, Lloyd G ^c   Eschenauer, Gregory A ^b,c   Clancy, Cornelius J ^a,b,e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; DORIPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; BETA-LACTAMASE KPC-2; CARBAPENEM DERIVATIVE; COLISTIN; OMPK36 PROTEIN, KLEBSIELLA PNEUMONIAE; PORIN;

ADD ON THERAPY; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; FEMALE; GENE INSERTION SEQUENCE; GENETIC VARIABILITY; GENOTYPE; GRAM NEGATIVE SEPSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INDEL MUTATION; KLEBSIELLA PNEUMONIAE; LOADING DRUG DOSE; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OMPK36 PORIN GENE; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SEQUENCE ANALYSIS; TREATMENT RESPONSE; BACTEREMIA; DRUG COMBINATION; DRUG EFFECTS; GENETICS; KLEBSIELLA INFECTIONS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; COLISTIN; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PORINS; RETROSPECTIVE STUDIES;

EID: 84923240004     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03894-14     Document Type: Article

References (15)

1. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y. 2012. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56:2108-2113. http://dx.doi.org/10.1128/AAC.06268-11.
2. Clancy CJ, Chen L, Shields RK, Zhao Y, Cheng S, Chavda KD, Hao B, Hong JH, Doi Y, Kwak EJ, Silveira FP, Abdel-Massih R, Bogdanovich T, Humar A, Perlin DS, Kreiswirth BN, Hong Nguyen M. 2013. Epidemiology and molecular characterization of bacteremia due to carbapenemresistant Klebsiella pneumoniae in transplant recipients. Am J Transplant 13:2619-2633. http://dx.doi.org/10.1111/ajt.12424.
3. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55:943-950. http://dx.doi.org/10.1093/cid/cis588.
4. Jernigan MG, Press EG, Nguyen MH, Clancy CJ, Shields RK. 2012. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 56:3395-3398. http://dx.doi.org/10.1128/AAC.06364-11.
5. Clancy CJ, Chen L, Hong JH, Cheng S, Hao B, Shields RK, Farrell AN, Doi Y, Zhao Y, Perlin DS, Kreiswirth BN, Nguyen MH. 2013. Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother 57:5258-5265. http://dx.doi.org/10.1128/AAC.01069-13.
6. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A. 2014. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322-2328. http://dx.doi.org/10.1128/AAC.02166-13.
7. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. 2014. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 20:862-872. http://dx.doi.org/10.1111/1469-0691.12697.
8. Centers for Disease Control and Prevention. 2013. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 62: 165-170.
9. Garonzik SM, Li J, Thamlikitkul V, Paterson DL, Shoham S, Jacob J, Silveira FP, Forrest A, Nation RL. 2011. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284-3294. http://dx.doi.org/10.1128/AAC.01733-10.
10. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 8th ed. Approved standard M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Fernandez-Cuenca F, Martinez-Martinez L, Conejo MC, Ayala JA, Perea EJ, Pascual A. 2003. Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother 51:565-574. http://dx.doi.org/10.1093/jac/dkg097.
12. Hong JH, Clancy CJ, Cheng S, Shields RK, Chen L, Doi Y, Zhao Y, Perlin DS, Kreiswirth BN, Nguyen MH. 2013. Characterization of porin expression in Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems. Antimicrob Agents Chemother 57:2147-2153. http://dx.doi.org/10.1128/AAC.02411-12.
13. Ho VP, Jenkins SG, Afaneh CI, Turbendian HK, Nicolau DP, Barie PS. 2011. Use of meropenem by continuous infusion to treat a patient with a Bla(kpc-2)-positive Klebsiella pneumoniae blood stream infection. Surg Infect (Larchmt) 12:325-327. http://dx.doi.org/10.1089/sur.2010.072.
14. Van Wart SA, Andes DR, Ambrose PG, Bhavnani SM. 2009. Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis 63:409-414. http://dx.doi.org/10.1016/j.diagmicrobio.2009.01.027.
15. Shlaes DM. 2013. New beta-lactam-beta-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci 1277:105-114. http://dx.doi.org/10.1111/nyas.12010.